Bacvax

What Bacvax does

BacVax, Inc. is a pre-clinical, Phoenix, Arizona-based biotechnology company (Delaware corporation) developing a pipeline of vaccines against bacterial infections. The company was founded around 2021 and was acquired by South Korea-based GPN Vaccines Inc. in August 2023, continuing to operate as a subsidiary. Its core technology is the Bacterial Vaccine Polypeptide (BVP) platform, a bioinformatics-driven Structural Vaccinology approach that maps bacterial surface proteins from genome and protein structure analyses to identify conserved, surface-exposed vaccine targets, then constructs multi-target polypeptide vaccines manufactured via recombinant protein production. The application scope is explicitly horizontal: the company plans to develop vaccines for both human bacterial infections (e.g., ear infections, nontypeable H. influenzae, COPD exacerbations) and animal health (food animals and companion animals, targeting antibiotic reduction). The lead product is a nontypeable H. influenzae vaccine candidate.

The BVP platform is backed by an Exclusive Patent License Agreement with the University of Arizona / Tech Launch Arizona covering PCT/US16/36180 (platform innovation) and PCT/US19/56298 (H. influenzae peptides), with the original research conducted at the University of Oklahoma and Phoenix Children's Hospital. The company is led by President and Chief Scientific Officer Dr. Terrence L. Stull (30+ years medical practice, 25+ years NIH-funded H. influenzae research), supported by a small scientific team of 1–10 employees total.

BacVax is still in development stage with no products on market, no disclosed revenue, and no disclosed funding rounds. The stated business model is asset-light: the company will engage partners on a per-product basis in licensing agreements covering product development, clinical studies, regulatory approval, and marketing, with future revenue expected from licensing/royalties and product sales. The company leases laboratory space in the Phoenix Biomedical Campus (Wexford Building) and communicates with prospective investors, community leaders, health experts, and business partners through its website and direct outreach.

Name

Bacvax

Legal name

BacVax, Inc.

Website

https://bacvax.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

1–10 employees

Short description

BacVax is a pre-clinical Phoenix-based biotechnology subsidiary of GPN Vaccines Inc. developing a Bacterial Vaccine Polypeptide (BVP) platform — a bioinformatics-driven Structural Vaccinology approach for designing multi-target bacterial vaccines — targeting human and animal health infections with no current vaccine options.

Ownership category

akta.pro rank

Product category

Bacterial Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Bacterial vaccine development
• Structural vaccinology platform
• Polypeptide vaccine technology
• Biotechnology research services
• Antibiotic alternative vaccines

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Licensing Agreements: BacVax plans to engage partners on a per product basis in licensing agreements for product development, clinical studies, regulatory approval, and marketing. The company will create a pipeline of new vaccines for select human and animal diseases and license to partners.
2. Vaccine Product Sales: Future revenue from sales of bacterial vaccines for human and animal health markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

BacVax is developing a pipeline of vaccines against bacterial infections using its proprietary Bacterial Vaccine Polypeptide (BVP) platform, a bioinformatics-driven Structural Vaccinology approach that maps bacterial surface proteins to identify conserved vaccine targets. The novel Bacterial Vaccine Polypeptide constructs are manufactured via cost-effective recombinant protein production and are designed to address bacterial infections with no current vaccine options, including ear infections and COPD exacerbations, for both human and animal health. The company engages partners on a per product basis through licensing agreements covering product development, clinical studies, regulatory approval, and marketing.

Product overview

BacVax is developing a pipeline of bacterial vaccines using its proprietary Bacterial Vaccine Polypeptide (BVP) Platform. The company employs a bioinformatics-driven Structural Vaccinology approach that maps bacterial surface proteins to identify conserved Vaccine Targets, which are then delivered via novel Bacterial Vaccine Polypeptide constructs manufactured through recombinant protein production. The technology is designed to address bacterial infections with no current vaccine options, targeting both human and animal health applications. The company holds an Exclusive Patent License Agreement from the University of Arizona for the BVP platform and additional patent applications targeting bacteria.

Differentiator

Problem solved

Functional benefit

Products and services

• Bacterial Vaccine Polypeptide (BVP) Platform An innovative 'omics' approach using bioinformatics-driven Structural Vaccinology to design vaccines that prevent bacterial infections by mapping bacterial surface proteins and constructing complex protein polypeptides targeting multiple bacterial surface proteins. Applicable to any organism and used to create a pipeline of new bacterial vaccines.
• Bacterial Vaccine Polypeptides (BVP Constructs) Novel vaccine constructs that efficiently deliver multiple Vaccine Targets from bacterial surface proteins, stimulating immune responses that attack bacteria at multiple sites. Manufactured via cost-effective recombinant protein production and designed to address bacterial infections with no current vaccine options for human and animal health.

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• University of Arizona, Tech Launch ArizonacoreStrategic or Co-development PartnerBacVax entered into an Exclusive Patent License Agreement with the University of Arizona, Tech Launch Arizona, for technologies reflected in patent applications PCT/US16/36180 and PCT/US19/56298. The University of Arizona administered patent applications on behalf of Phoenix Children's Hospital and the University of Oklahoma.
• Phoenix Children's HospitalminorStrategic or Co-development PartnerDr. Stull served as Senior Vice-President of Research at Phoenix Children's Hospital. The hospital collaborated on research that led to the BVP platform technology. Phoenix Children's Hospital co-administered patent applications with the University of Arizona and University of Oklahoma.
• University of OklahomaminorStrategic or Co-development PartnerDr. Stull was Chairman of the Department of Pediatrics at the University of Oklahoma Health Sciences Center for 22 years. The BVP technology was developed through research at the University of Oklahoma and Phoenix Children's Hospital. University of Oklahoma co-administered patent applications.

Scale indicators2 records

Recent moves5 records

Expansion highlights10 records

Emerging players

• MBF Therapeutics, Inc. Preclinical biotech developing immunotherapies and vaccines targeting infectious diseases, with oncology-immunology crossover. Comparable as an early-stage, platform-based vaccine/immunology company in similar development stage.
• Intravacc B.V. Dutch vaccine contract development organization offering vaccine platform technologies and translational services. Comparable as a vaccine-platform-focused organization pursuing licensing of enabling technology.
• HilleVax, Inc. Clinical-stage biotech developing vaccines for infectious diseases (lead program targeting norovirus). Comparable as an early-stage, single-platform vaccine developer pursuing differentiated indications through partnership-based commercialization models.
• Micron Biomedical, Inc. Clinical-stage biotech developing needle-free vaccine delivery technology for infectious diseases. Comparable as an early-stage vaccine-platform developer targeting infectious-disease prevention with a licensing-oriented business model.
• VLP Therapeutics, Inc. Preclinical/clinical-stage biotech developing VLP-based vaccine platforms (including for infectious diseases and pandemic preparedness). Comparable as a smaller platform-vaccine developer pursuing licensing and partnership-based commercialization.

Regional players

• Vaxxinova International BV: Netherlands-based animal health company developing and commercializing livestock and aquaculture vaccines. Comparable as an animal-vaccine specialist relevant to BacVax's food-animal applications.

Direct peers

• GPN Vaccines Inc. South Korea-based vaccine developer and BacVax's parent company following the August 2023 acquisition. GPN focuses on bacterial and viral vaccines (including its varicella program) and now owns the BVP platform, making it the most directly comparable peer in technology and category.

Broad incumbents

• Arcturus Therapeutics Holdings Inc. Clinical-stage mRNA medicines company with vaccine platform technology and infectious disease programs. Comparable as a platform-based vaccine developer licensing enabling technology across multiple disease targets.
• Phibro Animal Health Corporation: Public animal health company offering vaccines and pharmaceuticals for livestock and companion animals. Comparable as a commercial-stage animal-health vaccine developer relevant to BacVax's animal-health pipeline ambition.
• Boehringer Ingelheim Animal Health: Global animal-health leader with a large veterinary vaccine portfolio across livestock and companion animals. Comparable as a major incumbent BacVax's animal-health targets would compete against or be licensed into.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bacvax

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bacvax